Circulating levels of vascular endothelial growth factor and post‐stroke long‐term functional outcome

Circulating levels of vascular endothelial growth factor and post‐stroke long‐term functional outcome:

Abstract

Objectives

Vascular endothelial growth factor (VEGF) acts in angiogenesis and neuroprotection, although the beneficial effects on experimental ischemic stroke (IS) have not been replicated in clinical studies. We investigated serum VEGF (s‐VEGF) in the acute stage (baseline) and 3 months post‐stroke in relation to stroke severity and functional outcome.

Methods

The s‐VEGF and serum high‐sensitivity C‐reactive protein (hs‐CRP) concentrations were measured in patients enrolled in the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS) at the acute time‐point (median 4 days, N=492, 36% female; mean age, 57 years) and at 3 months post‐stroke (N=469). Baseline stroke severity was classified according to the National Institutes of Health Stroke Scale (NIHSS) and functional outcomes (3 months and 2 years) were evaluated using the modified Rankin Scale (mRS), dichotomized into good (mRS 0–2) and poor (mRS 3–6) outcomes. Multivariable logistic regression analyses were adjusted for covariates.

Results

The baseline s‐VEGF did not correlate with stroke severity but correlated moderately with hs‐CRP (r=0.17, p<0.001). The baseline s‐VEGF was 39.8% higher in total anterior cerebral infarctions than in lacunar cerebral infarctions. In binary logistic regression analysis, associations with 3‐month functional outcome were non‐significant. However, an association between the 3‐month s‐VEGF and poor 2‐year outcome withstood adjustments for age, sex, cardiovascular covariates, and stroke severity (per ten‐fold increase in s‐VEGF, odds ratio [OR], 2.56, 95% confidence interval [CI] 1.12–5.82) or hs‐CRP (OR 2.53, CI 1.15–5.55).

Conclusions

High 3‐month s‐VEGF is independently associated with poor 2‐year functional outcome but not with 3‐month outcome.